ABUS - Pangali EV/EBITDA Arbutus Biopharma Corporation

Arbutus Biopharma revenues are based on the commercialization of RNA therapy for hepatitis B. However, fierce competition with industry behemoths creates serious risks. Current licensing profits are minimal, and new growth catalysts are only beginning to emerge. Analyzing the company's EV/EBITDA ratio on the GURU.Markets chart, we note that the indicator reaches 2.99, which characterizes the asset's cost of capital and cash flows.

To minimize risks when building a position, it is essential to use EV/EBITDA, which compares the total enterprise value with its operating profit before depreciation and interest. In the case of Arbutus Biopharma (ABUS), assessing the business via EV/EBITDA trends allows for tracking the cost of capital for R&D projects, determining the extent to which the current market price aligns with the company's real assets given its dependence on clinical trials.